Request Demo
Recent blog posts
Latest Hotspot
8 min read
NCT07513285 Ibezapolstat Clostridioides difficile infection recurrence Clinical Landscape Report 2026: Design, Endpoints, Sponsor and Readout Outlook
26 August 2026
NCT07513285 clinical trial report covering Ibezapolstat, Phase 2, endpoints, sponsor, geography, readout timing and development white space.
Latest Hotspot
8 min read
NCT07513324 Pembrolizumab HPV16 positive Oropharyngeal Cancer Clinical Landscape Report 2026: Design, Endpoints, Sponsor and Readout Outlook
26 August 2026
NCT07513324 clinical trial report covering Pembrolizumab, Phase 2, endpoints, sponsor, geography, readout timing and development white space.
Latest Hotspot
8 min read
NCT07513454 HW211026 Actinic Keratosis Clinical Landscape Report 2026: Design, Endpoints, Sponsor and Readout Outlook
26 August 2026
NCT07513454 clinical trial report covering HW211026, Phase 2, endpoints, sponsor, geography, readout timing and development white space.
Latest Hotspot
8 min read
CTR20261321 TM471-1 Refractory Marginal Zone Lymphoma Clinical Landscape Report 2026: Design, Endpoints, Sponsor and Readout Outlook
26 August 2026
CTR20261321 clinical trial report covering TM471-1, Phase 2, endpoints, sponsor, geography, readout timing and development white space.
Latest Hotspot
8 min read
NCT07513623 Ganciclovir Uveitis, Anterior Clinical Landscape Report 2026: Design, Endpoints, Sponsor and Readout Outlook
26 August 2026
NCT07513623 clinical trial report covering Ganciclovir, Phase 2, endpoints, sponsor, geography, readout timing and development white space.
Latest Hotspot
8 min read
DPP4 Biologics Sequence Review Report 2026: Dipeptidyl peptidase 4 Similarity and Patent-Risk Signals
25 August 2026
A Biology Modality MCP review of DPP4 sequence similarity, pairwise alignment, patent-sequence signals and antibody–antigen evidence.
Latest Hotspot
8 min read
DLL1 Biologics Sequence Review Report 2026: Delta-like protein 1 Similarity and Patent-Risk Signals
25 August 2026
A Biology Modality MCP review of DLL1 sequence similarity, pairwise alignment, patent-sequence signals and antibody–antigen evidence.
Latest Hotspot
8 min read
DDR2 Biologics Sequence Review Report 2026: Discoidin domain-containing receptor 2 Similarity and Patent-Risk Signals
25 August 2026
A Biology Modality MCP review of DDR2 sequence similarity, pairwise alignment, patent-sequence signals and antibody–antigen evidence.
Latest Hotspot
8 min read
DDR1 Biologics Sequence Review Report 2026: Epithelial discoidin domain-containing receptor 1 Similarity and Patent-Risk Signals
25 August 2026
A Biology Modality MCP review of DDR1 sequence similarity, pairwise alignment, patent-sequence signals and antibody–antigen evidence.
Latest Hotspot
8 min read
CXCL12 Biologics Sequence Review Report 2026: Stromal cell-derived factor 1 Similarity and Patent-Risk Signals
25 August 2026
A Biology Modality MCP review of CXCL12 sequence similarity, pairwise alignment, patent-sequence signals and antibody–antigen evidence.
Latest Hotspot
8 min read
CX3CL1 Biologics Sequence Review Report 2026: Fractalkine Similarity and Patent-Risk Signals
25 August 2026
A Biology Modality MCP review of CX3CL1 sequence similarity, pairwise alignment, patent-sequence signals and antibody–antigen evidence.
Latest Hotspot
8 min read
CLDN25 Biologics Sequence Review Report 2026: Claudin-25 Similarity and Patent-Risk Signals
25 August 2026
A Biology Modality MCP review of CLDN25 sequence similarity, pairwise alignment, patent-sequence signals and antibody–antigen evidence.